Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Abbott Laboratories Q3 2026 Results: Net Income $920M, Down 44.0% YoY

Abbott Laboratories completed the $20.6 billion acquisition of Exact Sciences in March 2026, significantly expanding its cancer diagnostics portfolio. The company reported net earnings allocated to common shares of $2.9 billion for the first nine months of 2026, while managing a contract liability balance of $669 million and a goodwill increase to $32.6 billion.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue13,013.011,369.0
Profit before tax1,231.02,180.0
Net income920.01,644.0
EPS (diluted, $ a share)$0.53$0.94

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-44.0%
Revenue, year on year+14.5%
Operating margin10.4%
Source

10-Q filed with the SEC, NYSE: ABT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Abbott Laboratories: key numbers

Share price
$107.45Close, Nov 16
Market cap
$186B
Shares outstanding
1.73BLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Abbott Laboratories

All →
6:05 AM ET 8-K
Executive Compensation

Abbott Laboratories Executive Compensation

Abbott Laboratories extended the term of its Change in Control Agreements for its named executive officers through December 31, 2028. The agreement for Chairman and CEO Robert B. Ford was not extended and is set to expire on December 31, 2026.

Term
through Dec 2028
5:09 PM ET Form 4
Insider Selling

Abbott Laboratories EVP Mary K. Moreland Sells $406K of Stock

Mary K. Moreland, EVP, sold 3,500 shares of Abbott Laboratories at $116.00 a share, worth $406K in total on Nov 5, 2026. Shares held after the trade: 100,791 (-3.4%).

Value
$406K
Shares
3,500
Price
$116.00
Role
EVP
Holding change
-3.4%
Trade date
Nov 5, 2026
9:21 AM ET 8-K
Divestiture

Abbott Laboratories Divestiture

Abbott Laboratories announced its intention to separate its global Nutrition business into an independent, publicly traded company via a tax-free distribution to shareholders. The new entity will be a global leader in healthy nutrition with approximately $8.5 billion in annual sales and a portfolio including brands like Similac, Ensure, and PediaSure. The separation is expected to be completed by the end of 2027.

“As we continue to shape Abbott for the future, this separation will benefit both companies, setting each one up for maximum success in its respective market. Our Nutrition business has a unique opportunity to capitalize on the growing demand for healthy nutrition, and it will be better positioned as an independent company to more effectively direct its strategic resources across its priorities.”

Robert B. Ford, chairman and chief executive officer, Abbott
7:36 AM ET 8-K
Financial Results

Abbott Laboratories Financial Results

Abbott Laboratories reported third-quarter 2026 sales of $13.01 billion, a 14.5% increase on a reported basis, driven by strong performance in its Diagnostics and Medical Devices segments. The company tightened its full-year 2026 adjusted diluted EPS guidance to a range of $5.50 to $5.55 and highlighted several new product approvals, including the Libre Duo biowearable sensor.

Term
Q3 2026

“Abbott delivered strong third-quarter results, reflecting balanced growth across our portfolio. With strong performance across multiple businesses and a robust pipeline of innovation, we are well-positioned to deliver sustainable growth in the years ahead.”

Robert B. Ford, chairman and chief executive officer, Abbott

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.